Saul, thanks for reminding us of the time lapse that will be involved on the road to approval of any tx just entering phase 1 of clinical trials. This is important to know, and especially from the perspective of an investor.
Still, I believe that the two “compassionate use” occasions suggest the continuing possibility/likelihood of similar instances arising anywhere at any time. There are always patients who are too sick, with too little time remaining, who have failed all previous tx attempts. So why not try an existing “universal donor” product specific to their type of cancer in a last-ditch effort to save their life? If/when this does happen, then it will surely hit the news wires, just as it did in the two previous cases, at least if the product works as it did before. I do realize that such ad hoc administrations don’t count towards the drug’s approval, but they would serve to keep the company’s name in the news.